Impact of sampling time deviations on the prediction of the area under the curve using regression limited sampling strategies

2015 ◽  
Vol 36 (7) ◽  
pp. 417-428 ◽  
Author(s):  
Sarem Sarem ◽  
Fahima Nekka ◽  
Iman Saad Ahmed ◽  
Catherine Litalien ◽  
Jun Li
Keyword(s):  
Area Under The Curve ◽  
Sampling Time ◽  
Sampling Strategies ◽  
Limited Sampling

Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium

2009 ◽  
Vol 31 (5) ◽  
pp. 585-591 ◽  
Author(s):  
Brenda C M de Winter ◽  
Teun van Gelder ◽  
Ron A A Mathot ◽  
Petra Glander ◽  
Helio Tedesco-Silva ◽  
...  
Keyword(s):  
Mycophenolic Acid ◽  
Area Under The Curve ◽  
Sampling Strategies ◽  
Mycophenolate Sodium ◽  
Limited Sampling ◽  
Enteric Coated

Performance of Limited Sampling Strategies for Predicting Mycophenolic Acid Area Under the Curve in Thoracic Transplant Recipients

2008 ◽  
Vol 27 (3) ◽  
pp. 325-328 ◽  
Author(s):  
Lillian S.L. Ting ◽  
Nilufar Partovi ◽  
Robert D. Levy ◽  
Andrew P. Ignaszewski ◽  
Mary H.H. Ensom
Keyword(s):  
Mycophenolic Acid ◽  
Area Under The Curve ◽  
Sampling Strategies ◽  
Transplant Recipients ◽  
Limited Sampling

scholarly journals Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data

2021 ◽  
Vol 14 (2) ◽  
pp. 162
Author(s):  
Félicien Le Louedec ◽  
Fanny Gallais ◽  
Fabienne Thomas ◽  
Mélanie White-Koning ◽  
Ben Allal ◽  
...  
Keyword(s):  
Area Under The Curve ◽  
Sampling Strategy ◽  
Predictive Performance ◽  
Pharmacokinetic Profile ◽  
Limited Sampling Strategy ◽  
Joint Analysis ◽  
Therapeutic Drug ◽  
Post Dose ◽  
Limited Sampling ◽  
Three Samples

Therapeutic drug monitoring of ibrutinib is based on the area under the curve of concentration vs. time (AUCIBRU) instead of trough concentration (Cmin,ss) because of a limited accumulation in plasma. Our objective was to identify a limited sampling strategy (LSS) to estimate AUCIBRU associated with Bayesian estimation. The actual AUCIBRU of 85 patients was determined by the Bayesian analysis of the full pharmacokinetic profile of ibrutinib concentrations (pre-dose T0 and 0.5, 1, 2, 4 and 6 h post-dose) and experimental AUCIBRU were derived considering combinations of one to four sampling times. The T0–1–2–4 design was the most accurate LSS (root-mean-square error RMSE = 11.0%), and three-point strategies removing the 1 h or 2 h points (RMSE = 22.7% and 14.5%, respectively) also showed good accuracy. The correlation between the actual AUCIBRU and Cmin,ss was poor (r2 = 0.25). The joint analysis of dihydrodiol-ibrutinib metabolite concentrations did not improve the predictive performance of AUCIBRU. These results were confirmed in a prospective validation cohort (n = 27 patients). At least three samples, within the pre-dose and 4 h post-dose period, are necessary to estimate ibrutinib exposure accurately.

Determination of mycophenolate area under the curve by limited sampling strategy

2001 ◽  
Vol 33 (1-2) ◽  
pp. 1052-1053 ◽  
Author(s):  
S Yeung ◽  
K.L Tong ◽  
W.K Tsang ◽  
H.L Tang ◽  
K.S Fung ◽  
...  
Keyword(s):  
Area Under The Curve ◽  
Sampling Strategy ◽  
Limited Sampling Strategy ◽  
Limited Sampling

scholarly journals In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients

2021 ◽  
Author(s):  
T. Preijers ◽  
M. W. F. van Spengler ◽  
K. Meijer ◽  
K. Fijnvandraat ◽  
K. Fischer ◽  
...  
Keyword(s):  
In Silico ◽  
Half Life ◽  
Factor Ix ◽  
Hemophilia B ◽  
Weekly Dose ◽  
Sampling Strategies ◽  
Time Profiles ◽  
Limited Sampling ◽  
Individualized Dosing ◽  
Life Factor

Abstract Purpose Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become available. Prophylactic dosing of EHL-FIX concentrates can be optimized by assessment of individual pharmacokinetic (PK) parameters. To determine these parameters, limited sampling strategies (LSSs) may be applied. The study aims to establish adequate LSSs for estimating individual PK parameters of EHL-FIX concentrates using in silico evaluation. Methods Monte Carlo simulations were performed to obtain FIX activity versus time profiles using published population PK models for N9-GP (Refixia), rFIXFc (Alprolix), and rIX-FP (Idelvion). Fourteen LSSs, containing three or four samples taken within 8 days after administration, were formulated. Bayesian analysis was applied to obtain estimates for clearance (CL), half-life (t1/2), time to 1% (Time1%), and calculated weekly dose (Dose1%). Bias and precision of these estimates were assessed to determine which LSS was adequate. Results For all PK parameters of N9-GP, rFIXFc and rIX-FP bias was generally acceptable (range: −5% to 5%). For N9-GP, precision of all parameters for all LSSs was acceptable (< 25%). For rFIXFc, precision was acceptable for CL and Time1%, except for t1/2 (range: 27.1% to 44.7%) and Dose1% (range: 12% to 29.4%). For rIX-FP, all LSSs showed acceptable bias and precision, except for Dose1% using LSS with the last sample taken on day 3 (LSS 6 and 10). Conclusion Best performing LSSs were LSS with samples taken at days 1, 5, 7, and 8 (N9-GP and rFIXFc) and at days 1, 4, 6, and 8 (rIX-FP), respectively.

Sign in / Sign up

Export Citation Format

Share Document